Payment overview · 2025
General Payments
$374.27
16 reported records · 12 companies
Healthcare provider profile · identity verified
Jianfeng Wang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CAMBRIDGE, MA · NPI 1922395664
Verified facts
What the public records show
CMS Open Payments records show Jianfeng Wang, M.D. received $374.27 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Venclexta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lynparza by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.49 | 18.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.10 | 13.7% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $44.45 | 11.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.21 | 9.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.81 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.53 | 6.5% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $23.23 | 6.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.49 | 5.7% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $21.28 | 5.7% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $21.04 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.10 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.54 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.78 | 15 |
| Education | $68.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $68.49 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 44 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 165 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 30 |
| Letrozole | Letrozole | 108 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 100 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 31 |
| Tamoxifen Citrate | Tamoxifen Citrate | 97 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 27 |
| Venclexta | Venetoclax | 74 | suppressed |
| Anastrozole | Anastrozole | 63 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Revlimid | Lenalidomide | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | 16 |
| Lenalidomide | Lenalidomide | 44 | suppressed |
| Gabapentin | Gabapentin | 43 | 12 |
| Megestrol Acetate | Megestrol Acetate | 41 | 23 |
| Olanzapine | Olanzapine | 40 | 25 |
| Abiraterone Acetate | Abiraterone Acetate | 38 | suppressed |
| Hydroxyurea | Hydroxyurea | 37 | suppressed |
| Prednisone | Prednisone | 36 | 17 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 36 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 11 |
| Acyclovir | Acyclovir | 30 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 11 |
| Fentanyl | Fentanyl | 27 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Famotidine | Famotidine | 25 | 12 |
| Pomalyst | Pomalidomide | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Neupogen | Filgrastim | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 13 |
| Kisqali | Ribociclib Succinate | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 14 | suppressed |
| Inqovi | Decitabine/Cedazuridine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Brukinsa | Zanubrutinib | 13 | suppressed |
| Erleada | Apalutamide | 13 | suppressed |
| Ibrance | Palbociclib | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Lynparza | Olaparib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $374.27 · 16 records | AstraZeneca Pharmaceuticals LP | CARVYKTI, ELREXFIO, IMBRUVICA, IMFINZI, LUTATHERA, MONJUVI, OPDIVO, Orserdu, Padcev, SCEMBLIX, Trodelvy, ZYNYZ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error